AI Analysis
AI-generated analysis. Always verify with the original filing.
Nanobiotix reported full year 2025 financial results, extended its cash runway into early 2028, and provided updates on clinical progress for JNJ-1900 (NBTXR3) and its Curadigm Nanoprimer platform.
Key Takeaways
1Cash runway extended into early 2028 with €52.8 million in cash and equivalents as of December 31, 2025, assuming receipt of remaining $21 million from HCRx royalty financing.
2Revenue and other income was €32.6 million for 2025, compared to negative €7.2 million in 2024, driven by a non-cash accounting adjustment from the Janssen licensing agreement amendment.
3Net loss decreased 65% to €24.0 million (€0.50 per share) for 2025, primarily due to the revenue recognition impact and removal of NANORAY-312 funding obligations.
4Clinical data readouts expected in 2026 from Phase 1 and 2 studies in NSCLC, pancreatic cancer, melanoma, and esophageal cancer.
5Completed transfer of NANORAY-312 sponsorship in 4Q2025 and advanced Curadigm Nanoprimer platform with four new patent applications and CMC activities launch.